Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

About this update from Telomir Pharmaceuticals, Inc.

Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical Wilson's Disease Model.MIAMI, FL / ACCESS Newswire / May 20, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data showing that Telomir-Zn produced dose-dependent survival improvement across multiple endpoints in a Wilson's disease model, supporting the biological activity of Telomir-Zn in Wilson's disease. The study, titled "Intracellular copper redox modulation disrupts ROS-Ca²⁺ amplification in an ATP7B-deficient zebrafish model of Wilson's disease," was published in Advances in Redox Research.The publication reports that Telomir-Zn produced dose-dependent improvements across multiple endpoints in the preclinical Wilson's Disease model, including reduced copper-associated oxidative stress, reduced hepatic copper burden, improved liver injury biomarkers, attenuated intracellular calcium dysregulation, improved locomotor function, reduced tissue degeneration, and enhanced survival.The publication is available online at:Advances in Redox Research PublicationWilson's disease is a rare genetic disorder caused by mutation in the ATP7B gene, resulting in impaired copper excretion and toxic copper accumulation in the liver, brain, and other organs. The condition leads to progressive oxidative stress, mitochondrial dysfunction, inflammation, and multi-organ tissue injury. Current standard-of-care treatments, primarily copper chelation agents, address systemic copper levels but do not directly target the downstream oxidative and mitochondrial injury pathways associated with disease progression.According to the publication, Telomir-Zn demonstrated improvements across cellular and in vivo endpoints in the Wilson's disease model, including:Reduction of copper-induced reactive oxygen species (ROS) amplificationAttenuation of intracellular calcium dysregulation associated with oxidative stress signalingPreservation of metabolic viability under copper and peroxide challengeReduction of hepatic copper accumulationImprovement ...

View stock analysis, news, and events for Telomir Pharmaceuticals, Inc.